Abrégé

The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 35/761 - Adénovirus
• A61K 38/00 - Préparations médicinales contenant des peptides
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates to compounds based on a recombinant form of the CCP6 region of C4BP and an oligomerization domain for use in the prevention and/or treatment of immunological diseases. Moreover, the invention relates to methods for obtaining tolerogenic dendritic cells and tolerogenic macrophages using the compounds of the invention and to the cells obtained by these methods and their therapeutic uses.

Classes IPC  ?

• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 5/0784 - Cellules dendritiquesLeurs progéniteurs

Abrégé

The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Compounds derived from ursodeoxycholic acid of formula (I) and to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.

Classes IPC  ?

• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol

Abrégé

The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.

Classes IPC  ?

• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C07K 14/075 - Adénoviridae
• A61K 35/761 - Adénovirus
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Abrégé

The invention relates to in vitro methods for detecting bacteremia, for selecting a therapy for a subject with cystic fibrosis or for a subject with systemic inflammatory response syndrome and for selecting a subject with cystic fibrosis or with systemic inflammatory syndrome for a particular therapy based on the expression levels of a gene selected from tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF in a blood sample from the subject. The invention also relates to a kit comprising a TLR-4 agonist and a reagent specific for determining the level of at least one cytokine selected from the group consisting of tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF and to the uses of this kit.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

It relates to a compound of formula (I), particularly asenapine, or a pharmaceutically acceptable salt thereof, or any stereoisomer or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically acceptable salts, for use in the treatment and/or prevention of cancer. It also relates to a drug combination of a compound of formula (I), its stereoisomers and/or salts thereof, and one or more anticancer agents selected from the group consisting of chemotherapy agents, immunotherapy agents, and hormone therapy agents; and to pharmaceutical compositions and to a kit of parts comprising this combination, as well as the use of the drug combination, the compositions, or kit of parts for use in the treatment and/or prevention of cancer.

Classes IPC  ?

• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
• A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 33/243 - PlatineSes composés
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

The present invention provides S-methyl-L-ergothioneine for use in diagnosis and/or prognosis. The invention also provides a method for the diagnosis and/or prognosis of a renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and methods for deciding or recommending whether to initiate a therapeutic intervention or for determining the efficacy of a therapeutic intervention. It is also herein provided ergothioneine for use in the treatment and/or prevention of a renal lithiasis or an aminoaciduria, and ergothioneine for use in combination therapy.

Classes IPC  ?

• A61K 31/4172 - Acides imidazole-alkanecarboxyliques, p. ex. histidine
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 31/223 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'alpha-amino-acides
• A61K 31/16 - Amides, p. ex. acides hydroxamiques
• A61P 13/04 - Médicaments pour le traitement des troubles du système urinaire de l'urolithiase

Abrégé

The present invention belongs to the field of genetic therapy. In particular, the invention refers to EphA2 specific RNA-based constructs, which are useful for the treatment, prevention and diagnosis of EphA2 expressing cancers.

Classes IPC  ?

• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

The present invention provides a compound comprising a fusion polypeptide of formula (I): R1-L-R2-Fc wherein R1, which is at the N-terminal end of the polypeptide, is PD-L2 or a PD1-binding fragment thereof, L is a peptide linker, R2 is CTLA-4 or a CD80/CD86-binding fragment thereof, and Fc, which is at the C-terminal end of the polypeptide, is an immunoglobulin Fc domain. The present invention also provides a dimer of the compound, a polynucleotide which encodes the polypeptide, a vector comprising the polynucleotide, a host cell which contains the polynucleotide, a composition and a kit comprising the compound. The invention also provides the compound or the dimer for use in therapy, diagnosis and prognosis, in particular for the treatment of autoimmune diseases or transplant rejection.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

A composition is for improving the culture and implantation of mammalian embryos. The composition includes one or more of the fractions of human plasma fractionation using the Cohn method wherein in the composition human serum albumin (HSA) is between 90% and 96% of the total proteins in the composition, alfa and beta globulins are between 3.5% and 9.99% of the total proteins in the composition, and gamma globulin is between 0.01% and 0.5% of the total proteins in the composition.

Classes IPC  ?

• C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux

Abrégé

The present invention relates to an in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject based on the determination of the methylation pattern in certain regions of mitochondrial DNA from the subject. Finally, the present invention relates to nucleic acids suitable for application of the invention.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

SIGLEC17P AP4S1, ZMYM6, USP21, DMAP1, SUPT5H, TP53BP1, NECAB3, BTD, DACT1SIGLEC17P SIGLEC17P and/or of at least one of its associated downstream coding genes is higher than a reference value, this is indicative of renal allograft antibody-mediated rejection.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to methods useful for predicting the risk of local invasion and/or metastasis induced by an antiangiogenic treatment in a patient who suffers from cancer, or for predicting the response to an antiangiogenic therapy, wherein the methods comprise the determination of the expression level of ALDH1A3, as well as methods for providing personalized medicine to said patients. These methods can be used to identify those patients who are at a high risk of local invasion and/or metastasis. The identification of this subgroup of patients may guide the selection of therapies, improving financial and health outcomes. The invention relates as well to the use of reagents for carrying out the predictive methods.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Presented are methods of assessing a deficit in DNA damage repair capability in cancer cells. Cancer cells having this DNA damage repair phenotype have increased susceptibility to certain treatments, including genotoxic treatments, treatment with PARP1 inhibitors, and immunotherapies. The methods encompass the use of novel gene expression signatures that enable facile and rapid determination of the DNA damage repair phenotype in cancer cells of a sample. By these methods, subjects having cancer that is amenable to genotoxic treatment, PARP1 inhibition, or immunotherapy may be identified and administered a suitable treatment. Also disclosed is a method of inducing the DNA damage repair deficit phenotype in cancer cells to sensitize them to various treatments.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/6834 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide
• A61K 33/243 - PlatineSes composés
• A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
• A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules

Abrégé

The invention relates to in vitro methods for detecting bacteremia, for selecting a therapy for a subject with cystic fibrosis or for a subject with systemic inflammatory response syndrome and for selecting a subject with cystic fibrosis or with systemic inflammatory syndrome for a particular therapy based on the expression levels of a gene selected from 5 tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF in a blood sample from the subject. The invention also relates to a kit comprising a TLR-4 agonist and a reagent specific for determining the level of at least one cytokine selected from the group consisting of tumor necrosis factor alpha (TNFα), IL-1b, IL-10, CCL2, interferon beta (IFN-β), IL-17, IL-2, IL-4 and VEGF and to the uses 10 of this kit.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

in vitro in vitro method and kits for the prognosis of amyotrophic lateral sclerosis (ALS), based on the expression or activity of ELOVL6 ( Elongation of Very Long chain fatty acids protein 6).

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.

Classes IPC  ?

• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol

Abrégé

The invention relates to compounds based on a recombinant form of the CCP6 region of C4BP and an oligomerization domain for use in the prevention and/or treatment of immunological diseases. Moreover, the invention relates to methods for obtaining tolerogenic dendritic cells and tolerogenic macrophages using the compounds of the invention and to the cells obtained by these methods and their therapeutic uses.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/02 - Immunomodulateurs
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 5/0786 - MonocytesMacrophages
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/12 - Gènes codant pour des protéines animales

Abrégé

The invention relates to compounds based on a recombinant form of the CCP6 region of C4BP and an oligomerization domain for use in the prevention and/or treatment of immunological diseases. Moreover, the invention relates to methods for obtaining tolerogenic dendritic cells and tolerogenic macrophages using the compounds of the invention and to the cells obtained by these methods and their therapeutic uses.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The present invention provides S-methyl-L-ergothioneine for use in diagnosis and/or prognosis. The invention also provides a method for the diagnosis and/or prognosis of a renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and methods for deciding or recommending whether to initiate a therapeutic intervention or for determining the efficacy of a therapeutic intervention. It is also herein provided ergothioneine for use in the treatment and/or prevention of a renal lithiasis or an aminoaciduria, and ergothioneine for use in combination therapy.

Classes IPC  ?

• A61K 31/4172 - Acides imidazole-alkanecarboxyliques, p. ex. histidine
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres

Abrégé

The present invention provides S-methyl-L-ergothioneine for use in diagnosis and/or prognosis. The invention also provides a method for the diagnosis and/or prognosis of a renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and methods for deciding or recommending whether to initiate a therapeutic intervention or for determining the efficacy of a therapeutic intervention. It is also herein provided ergothioneine for use in the treatment and/or prevention of a renal lithiasis or an aminoaciduria, and ergothioneine for use in combination therapy.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to methods for selecting a restrictive or a malabsorptive bariatric surgical procedure for a patient in need thereof, wherein the method comprises determining the circulating succinate level in a biofluid sample from said patient. These methods can be used to identify those subgroups of patients who are more likely to benefit from a restrictive or a malabsorptive bariatric surgical procedure, thereby improving financial and health outcomes. The invention also relates to methods for predicting, before bariatric surgery, type 2 diabetes remission after restrictive bariatric surgery in a patient suffering from type 2 diabetes. Finally, the invention relates to uses of circulating succinate levels as an effective predictive factor for selecting a bariatric surgical procedure for a patient, as well as an informative biomarker for predicting, before bariatric surgery, type 2 diabetes remission after restrictive bariatric surgery in a patient suffering from type 2 diabetes.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention belongs to the field of genetic therapy. In particular, the invention refers to EphA2 specific RNA-based constructs, which are useful for the treatment, prevention and diagnosis of EphA2 expressing cancers.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider

Abrégé

The present invention belongs to the field of genetic therapy. In particular, the invention refers to EphA2 specific RNA-based constructs, which are useful for the treatment, prevention and diagnosis of EphA2 expressing cancers.

Classes IPC  ?

• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The present invention relates to the implantation of mammalian embryos using a composition which comprise one or more of the fractions of human plasma fractionation using the Cohn method wherein in said composition human serum albumin (HSA) is between 90 % and 96 % of the total proteins in the composition, alfa and beta globulins are between 3.5 % and 9.99 % of the total proteins in the composition, and gamma globulin is between 0.01 % and 0.5 % of the total proteins in the composition. In addition, the present invention relates to the preparation method and use of said composition in the culture of mammalian embryos.

Classes IPC  ?

• C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux

Abrégé

The present invention relates to the implantation of mammalian embryos using a composition which comprise one or more of the fractions of human plasma fractionation using the Cohn method wherein in said composition human serum albumin (HSA) is between 90 % and 96 % of the total proteins in the composition, alfa and beta globulins are between 3.5 % and 9.99 % of the total proteins in the composition, and gamma globulin is between 0.01 % and 0.5 % of the total proteins in the composition. In addition, the present invention relates to the preparation method and use of said composition in the culture of mammalian embryos.

Classes IPC  ?

• C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux

Abrégé

The present invention provides a compound comprising a fusion polypeptide of formula (I): R1-L-R2-Fc wherein R1, which is at the N-terminal end of the polypeptide, is PD-L2 or a PD1- binding fragment thereof, L is a peptide linker, R2 is CTLA-4 or a CD80/CD86-binding fragment thereof, and Fc, which is at the C-terminal end of the polypeptide,is an immunoglobulin Fc domain.The present invention also provides a dimer of the compound, a polynucleotide which encodes the polypeptide, a vector comprising the polynucleotide, a host cell which contains the polynucleotide, a composition and a kit comprising the compound. The invention also provides the compound or the dimer for use in therapy, diagnosis and prognosis,in particular for the treatment of autoimmune diseases or transplant rejection.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

2. Pharmaceutical compositions comprising from 0.45 mg to 18.90 mg of these compounds for the prevention and/or treatment of these diseases are also described.

Classes IPC  ?

• A61K 38/13 - Cyclosporines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

In vitroin vitroin vitro method for the prediction of response to neoadjuvant chemotherapy (NAC), or for selecting a therapy, for triple negative breast cancer patients (TNBC). The method of the invention comprises determining the methylation status of the gene FERD3L and/or TRIP10 in a biological sample obtained from a patient, wherein a higher level of methylation of the gene FERD3L and/or TRIP10, as compared with the level of methylation of at least one of said genes in non-responder patients, is indicative of response to NAC in TNBC patients.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Produits et services

Software platform for computers, social networks and mobile telephones, downloadable software. Internet platform access services.

Produits et services

Downloadable software for the provision of telemedicine and for tracking, monitoring, reporting, and communicating patient vital signs, patient information and symptoms between patients and healthcare providers Internet platform access services, namely, internet service provider services in the nature of transmitting information via the Internet in the fields of telemedicine and telehealth

Produits et services

(1) Computer software platforms for use in providing multiple user access to a global computer information network for social networking and via mobile telephones. (1) Providing access to the Internet.

Abrégé

The invention relates to compounds for use in the prevention and/or treatment of immunological diseases, particularly rheumatoid arthritis systemic lupus erythematosus and lupus nephritis, characterized by the subcutaneous administration of isoforms of C4BP lacking the beta chain or polypeptides comprising the CCP6 region of the alpha chain of C4BP no more than once a week or at a dose ranging from 0.24 mg/m2 to 9.99 mg/m2. The invention also relates to pharmaceutical compositions comprising from 0.45 mg to 18.90 mg of said compounds for the prevention and/or treatment of said diseases.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The invention relates to compounds for use in the prevention and/or treatment of immunological diseases, particularly rheumatoid arthritis systemic lupus erythematosus and lupus nephritis, characterized by the subcutaneous administration of isoforms of C4BP lacking the beta chain or polypeptides comprising the CCP6 region of the alpha chain of C4BP no more than once a week or at a dose ranging from 0.24 mg/m2 to 9.99 mg/m2. The invention also relates to pharmaceutical compositions comprising from 0.45 mg to 18.90 mg of said compounds for the prevention and/or treatment of said diseases.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Disclosed is an in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject based on the determination of the methylation pattern in certain regions of mitochondrial DNA from the subject or the determination of the nucleotide at the polymorphic position 16519 in the mitochondrial DNA of the subject. Also, disclosed are nucleic acids suitable for the in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.

Classes IPC  ?

• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 35/761 - Adénovirus
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 14/075 - Adénoviridae
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

It relates to a topical gel composition comprising lidocaine or its pharmaceutically acceptable salts and diclofenac or its pharmaceutically acceptable salts, together with one or more pharmaceutically acceptable excipients or carriers for use in the treatment of pre- and postoperative pain in the benign anorectal surgery by topical rectal administration using a specific dosage regime which consist of the administration twice per day during three days and once per day from the fourth day of treatment of the composition. It also relates to a specific topical lipogel composition especially suitable for this use as well as to a kit comprising the previous lipogel and a second pharmaceutical composition comprising lidocaine or a salt pharmaceutically acceptable thereof together with one or more pharmaceutically acceptable excipients or carriers.

Classes IPC  ?

• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires

Abrégé

The present invention is directed to a diagnostic method for adrenoleukodystrophy in a subject based on the determination of the levels of different markers. The invention also provides a method for monitoring the progression of an adrenoleukodystrophy, a method for monitoring the effect of an adrenoleukodystrophy therapy and fingolimod, an analogue, metabolite or derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of anadrenoleukodystrophy.

Classes IPC  ?

• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes

Abrégé

The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis,monitoringand prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis,monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The invention relates to a method for the prognosis of hepatocellular carcinoma in an isolated sample of a subject, the method comprising providing a DNA methylation signature, said signature obtained from the qualitative and quantitative methylation analysis of 36 selected CpG sites. The invention also disclosesparticular methods in which a Mortality Index score is provided from said signature.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patient suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVRl) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.

Classes IPC  ?

• A61K 35/761 - Adénovirus
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• A61P 37/04 - Immunostimulants
• C07K 14/075 - Adénoviridae
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 15/34 - Protéines de virus à ADN
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/861 - Vecteurs adénoviraux

Abrégé

The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVRl) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C07K 14/075 - Adénoviridae

Abrégé

The invention relates to an in vitro method for diagnosing or determining the risk of a subject developing a neurodegenerative disease based on the determination of the methylation pattern in certain regions of the mitochondrial DNA of said subject or based on the determination of the nucleotide in the polymorphic position 16519 of the mitochondrial DNA of said subject. The invention further relates to nucleic acids suitable for implementing the invention.

Classes IPC  ?

• C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
• C12Q 1/6813 - Tests d’hybridation
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to an in vitro method for diagnosing or determining the risk of a subject developing a neurodegenerative disease based on the determination of the methylation pattern in certain regions of the mitochondrial DNA of said subject or based on the determination of the nucleotide in the polymorphic position 16519 of the mitochondrial DNA of said subject. The invention further relates to nucleic acids suitable for implementing the invention.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

System for providing oxygen to a patient, comprising a sensing device (41) having an oxygen sensor (41) for obtaining one or more measurements of a level of oxygen in patient's blood, ari oxygen provider (45) for providing oxygen to the patient, and a control unit (40). The control unit (40) is configured to receive the level of oxygen in blood from the oxygen sensor (41), and to determine a parameter representative of oxygen insufficiency by comparing the level of oxygen in blood with an oxygen level threshold. The control unit (40) is further configured to determine an oxygen need depending at least on the parameter representative of oxygen insufficiency, and to cause the oxygen provider (45) to continuously provide the oxygen need to the patient until the oxygen need is determined to be substantially null.

Classes IPC  ?

• A61M 16/06 - Masques respiratoires ou pour l'anesthésie
• A61M 16/00 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p. ex. ventilateursTubes trachéaux

Abrégé

The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 and R1' are both H, or R1 and R1' are taken together forming a biradical of formula -CH2-C(R4)=CH-; R2 and R3 are radical independently selected from the group consisting of H, F, CI and (C1-C4)-alkyl; R4 is a (C1-C2)-alkyl radical; and n is an integer from 2 to 15, are useful for the treatment of a neurodegenerative disorder such as Alzheimer's disease.

Classes IPC  ?

• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 219/10 - Atomes d'azote liés en position 9
• C07D 221/18 - Systèmes cycliques d'au moins quatre cycles

Abrégé

The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the C4b-binding protein (C4BP) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease. Moreover, the invention relates also the use of factor H for the treatment of immunological diseases. In addition, the invention relates to tolerogenic dendritic cells obtained using the C4BP isoform lacking beta chain, the peptides and fragments thereof and factor H and to the therapeutic uses of said cells.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12N 5/0784 - Cellules dendritiquesLeurs progéniteurs
• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques

Abrégé

Systems and methods for neuropathic pain treatment using neuromodulation are provided. In one embodiment, a wireless micro-neurostimulator is provided that is comprised of microelectrode(s) placed inside nerve(s) for neurostimulation, to treat peripheral neuropathic pain and other lesions related to the nerve. The micro-neurostimulator is implanted percutaneously and placed by ultrasound-guided puncture. It is recharged by induction charging, which allows recharging through the skin without wires penetrating the skin. Because the device is placed inside the nerve, however, the need for recharging is minimized. Advantageously, there is limited displacement of the micro-neurostimulator within the nerve due to muscle movement, and constant stimulus is provided because the device is moved with the nerve.

Classes IPC  ?

• A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques

Abrégé

The present invention relates to methods for determining the probability of transplant rejection based on the determination in the subject recipient of the transplant of the levels of antibodies specific for hyaluronic acid. The invention relates as well to methods for attenuating transplant rejection and compositions to prevent transplant rejection based on the depletion of anti- hyaluronic acid antibodies from the subject.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a box for protecting at least one connection used for the interconnection of catheters and/or drains and infusion and/or drainage equipment respectively, said box comprising a casing and characterised in that it comprises an element for projecting antiseptic liquid towards the connection, arranged inside the casing.

Classes IPC  ?

• A61M 39/16 - Raccords ou accouplements pour tubes avec des dispositions pour la désinfection ou la stérilisation

Abrégé

The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patiente suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to a method for generating a path for a virtual bronchoscopy, comprising generating a model of a tracheobronchial tree and a model of a bronchoscope. The model of the tracheobronchial tree comprises a representation of the walls of the tree and of a target zone. The model of the bronchoscope comprises a representation of a viewing end (tip) of the bronchoscope using a kinematic chain of inter-articulated rigid bodies. The rigid bodies include at least a base and a viewing body. The rotation of the articulations represents a tip bending movement. The method also comprises calculating a sequence of chain movements that moves the viewing body towards the target without any of the rigid bodies passing beyond the walls of the tracheobronchial tree, each segment being calculated by applying at least one chain articulation rotation value and a chain forward movement.

Classes IPC  ?

• G06F 19/12 - pour la modélisation ou la simulation en biologie des systèmes, p.ex. modèles probabilistes ou dynamiques, réseaux régulateurs de gènes, réseaux d'interaction protéique ou réseaux métaboliques
• G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
• G06T 17/10 - Description de volumes, p. ex. de cylindres, de cubes ou utilisant la GSC [géométrie solide constructive]

Abrégé

The present invention is directed to pioglitazone, or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising pioglitazone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment and/or prevention of an adrenoleukodystrophy.

Classes IPC  ?

• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The present invention relates to peptides derived from the RCAN proteins for their use in medicine and in the treatment of diseases in a subject occurring with uncontrolled cell proliferation, immune disorders, cardiovascular disorders, neurodegenerative diseases, alopecia, undesired angiogenesis and undesired PMN infiltration.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to mesenchymal stem cells (MSCs) that have been genetically modified to express ST2 or parts thereof for use in the treatment of pulmonary immunoinflammatory diseases, wherein said mesenchymal stem cells are not human embryo stem cells. The present invention also relates to pharmaceutical compositions that comprise said mesenchymal stem cells.

Classes IPC  ?

• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées

Abrégé

The present invention is related to methods for prevention and/or treatment of a number of diseases, such as lupus nephritis, ischemia/reperfusion injury and sepsis, based on the silencing of CD40 using different RNA silencing strategies.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

The invention is related to methods and compositions involving CD40 silencing by RNA interference and an immunosuppressive agent for preventing the rejection of kidney transplant in mammals and increasing tolerance in a recipient mammal to a kidney transplant.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the C4b-binding protein (C4BP) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease. Moreover, the invention relates also the use of factor H for the treatment of immunological diseases. In addition, the invention relates to tolerogenic dendritic cells obtained using the C4BP isoform lacking beta chain, the peptides and fragments thereof and factor H and to the therapeutic uses of said cells.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12N 5/0784 - Cellules dendritiquesLeurs progéniteurs

Abrégé

The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the C4b-binding protein (C4BP) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease. Moreover, the invention relates also the use of factor H for the treatment of immunological diseases. In addition, the invention relates to tolerogenic dendritic cells obtained using the C4BP isoform lacking beta chain, the peptides and fragments thereof and factor H and to the therapeutic uses of said cells.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 5/0784 - Cellules dendritiquesLeurs progéniteurs
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression

Abrégé

The present invention relates to the diagnosis and prognosis of metastasis in breast cancer based in the determination of the expression level of PRDX2gene. It also relates to a method for diagnosis and prognosis of metastasis in breast cancer based in the determination of the expression level of ERp57/GRP58gene. Lastly, the invention refers to the use of PRDX2and/or PRDX3 inhibitors and a ROS-generating agent for the treatment and/or prevention of lung metastasis in breast canceras well as to the use of ERp57/GRP58 inhibitors for the treatment and/or prevention of bone metastasis in breast cancers.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously results in tumour volume regressions. Therefore, the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.

Classes IPC  ?

• C12N 15/861 - Vecteurs adénoviraux
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 15/60 - Lyases (4)
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 35/761 - Adénovirus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
• C12N 15/86 - Vecteurs viraux
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention is a combination of N-acetylcysteine (NAC) and alpha lipoic acid (LA), or pharmaceutically acceptable salts thereof, for the prevention and/or treatment of a disease with axonal damage and concomitant oxidative lesions in a mammal, in particular X-linked adrenoleukodystrophy (X-ALD). The mouse model of X-ALD shows a late- onset neurological phenotype of the disease of locomotor deficit and axonal degeneration as predominant pathologies characteristic of the disease. The inventors have found that treatment of mouse models of X-ALD with these two active principles achieves reversal of oxidative stress and of the derived lesions to proteins of the spinal marrow as target organ of the disease, on the one hand, moreover however achieving prevention and reversal of axonal degeneration and furthermore correcting locomotor deficit presented by the mouse model of the disease, that is to say, the clinical symptomatology thereof.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/861 - Vecteurs adénoviraux